Case number# PHEH2014US021380, is an initial report received from a consumer (patient) via a patient oriented 
program Gilenya Go Program (POP ID POP00002581) on 22 Oct 2014 and a follow up report received from a 
consumer (patient) on 20 Nov 2014, with a follow up report received from a consumer (patient) on 21 Jan 2015, via 
a patient oriented program Gilenya Go Program (POP ID POP00002581), with follow up report with a targeted 
follow up checklist of ischemic heart disease/ myocardial infarction received from a physician on 02 Feb 2015, with 
a follow up report received from a healthcare professional along with a targeted follow up checklist for blood 
dyscrasias and myeosuppression on 30 Mar 2015.
This report refers to a 43 year old female patient. The patient had no history of cardiovascular (CV) effects for the 4 
years on the drug. Historical condition included anxiety, family stress and depression.
This polymedicated patient received Gilenya (fingolimod) capsule for the treatment of multiple sclerosis since 
around 4 years at a dose of 0.5 mg (oral) QD and again received Gilenya (expiration date 07 Nov 2015) from 10 
Sep 2014 at same dose. The patient also received Gilenya from 23 Sep 2014 (Expiry date 31 Dec 2015, batch 
S0070A) at same dose. The patient also received Celexa (citalopram hydrobromide) for an unknown indication 
from an unknown date at a dose of 20 mg.
On an unknown date in Sep 2014, the patient had not had much of an appetite (decreased appetite) and did not 
gained weight. The patient did not think it was due to Gilenya but due to family stress. The patient stated his 
leukocytes/ white blood count was very low according to her doctor, extremely low (WBC decreased). The patient 
had chronic panic attacks and anxiety. The patient had diarrhoea with any anxious events. The patient had fallen 
couple of times recently (fall) which were unwitnessed. The treatment with Gilenya was discontinued on an 
unknown date in Nov 2014, due to the adverse events and the fact that Celexa was contraindicated with Gilenya. 
Her physician was aware that she stopped Gilenya and the reason why she stopped. On an unknown date, the 
Print Time: 26-MAY-2016 01:56 PM If a field is blank, there is no data for that field Page 662 of 675
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
patient developed myocardial infarction. On an unknown date, the patient had nausea and vomiting. On 21 Jan 
2015, the patient had GI side effects with weight loss. It was reported that, the patient did not want to be on Gilenya 
and wanted to shift on Tysabri (natalizumab) but was afraid as she was JC virus positive. Action taken for Celexa 
was unknown.
The outcome of the events decreased appetite, panic attack, white blood count decreased, anxiety, diarrhea and 
fall was reported as complete recovery on an unknown date in Nov 2014. The outcome of the event GI side effects 
with weight loss was reported as complete recovery on 22 Jan 2015. The outcome of the event myocardial 
infarction was unknown. The outcome of the events nausea, vomiting and JC virus test positive was not reported. 
The seriousness assessment of events was not reported. The seriousness assessment of event myocardial 
infarction was upgraded based on the NVS IME list. Seriousness assessment of JC virus test positive was 
upgraded based on information available in the source documents. The causality of the events decreased appetite, 
panic attack, white blood count decreased, anxiety, diarrhea and fall were reported as not suspected to Gilenya. 
The causality of the event GI side effects with weight loss was reported as suspected and causality of the other 
events was not reported.
Follow up report received from a consumer (patient) on 20 Nov 2014 Added new event WBC decreased.
Follow up report received from a consumer (patient) on 21 Jan 2015 The events fall, diarrhea and panic attack 
were added. All the concomitant drugs were added.
Follow up received from a physician on 02 Feb 2015. Added historical conditions (anxiety and depression), new 
events (myocardial infarction, GI side effects with weight loss, nausea and vomiting) and amended narrative 
accordingly.
Following an internal review done on 11 Feb 2015 for the data received on 02 Feb 2015, the case 
PHEH2015US002211 was found to be a duplicate of the case PHEH2014US021380. So all the information from 
case PHEH2015US002211 was merged in the case PHEH2014US021380 and the case PHEH2015US002211 was
deactivated.
Follow up report received from a healthcare professional along with a targeted follow up checklist for blood 
dyscrasias and myeosuppression on 30 Mar 2015. Updated patient demography (weight and height) and suspect 
drug information (stop date), events decreased appetite, panic attack, white blood count decreased, diarrhea and 
fall information (start date, stop date, outcome and causality). Added event anxiety.
Print Time: 26-MAY-2016 01:56 PM If a field is blank, there is no data for that field Page 663 of 675
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information